Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07153471 | A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee | PHASE3 | RECRUITING | 800 | — | — | Sep 15, 2025 | May 1, 2028 | Jun 4, 2026 | 95 | United States, Canada +6 |
| Arm | Type | Description |
|---|---|---|
| Orforglipron (GZT1) | EXPERIMENTAL | Participants will receive orforglipron orally |
| Placebo (GZT1) | PLACEBO_COMPARATOR | Participants will receive placebo orally |
| Orforglipron (GZT2) | EXPERIMENTAL | Participants will receive orforglipron orally |
| Placebo (GZT2) | PLACEBO_COMPARATOR | Participants will receive placebo orally |
| Name | Type | Description |
|---|---|---|
| Orforglipron | DRUG | Administered orally |
| Placebo | DRUG | Administered orally |
Inclusion Criteria: * Have a body mass index (BMI) of 27 kilograms per square meter (kg/m2) or higher at screening * Have tried at least once to lose weight through diet but were unsuccessful * Have osteoarthritis of the knee and at least one of the following conditions: * Be over 50 years old ...